THERAPY DOSSIER · th-933b1afc2b63

Amnion-derived cellular cytokine suspension (ACCS), the secretome of human amnion-derived multipotent progenitor cells

Biologic · Cell-free secretome of amnion-derived multipotent progenitor cells, delivering a multi-cytokine/growth factor mixture; biologic mixture with no single ChEMBL entity. Clinically developed as ST266 by Noveome Biotherapeutics (formerly Stemnion).

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: Cell-free secretome of amnion-derived multipotent progenitor cells, delivering a multi-cytokine/growth factor mixture; biologic mixture with no single ChEMBL entity. Clinically developed as ST266 by Noveome Biotherapeutics (formerly Stemnion).
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: ACCS; ST266; Amnion-derived cellular cytokine solution; AMP cell secretome
Note: Not recorded

Clinical trials 2

1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02389777 ↗Injury indicationPHASE2completed

Effect of ACCS in UV-induced Inflammation

Skin Burns

Enrolment: 10 · Results not recorded

NCT02369861 ↗PHASE1completed

Amnion-derived Cellular Cytokine Solution (ACCS) Eye Drops in the Treatment of Dry Eye

Dry Eye Syndrome

Enrolment: 30 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22847087 ↗2012Mixed findings

Long-term administration of amnion-derived cellular cytokine suspension promotes functional recovery in a model of penetrating ballistic-like brain injury.

RatTBIPenetrating / ballisticSprague-DawleyMaleContinuous intracerebral infusionOptimal infusion rate 1 microlitre per hourInitiated 15 minutes after injury in the main experiment; a separate experiment…

Model: Penetrating ballistic-like brain injury

ACCS was thermally stable for 1 week at 37 degrees C and protected neurites against staurosporine toxicity in vitro. Long-term infusion at 1 microlitre per hour significantly reduced injury-induced neuropathology and motor abnormalities but was not sufficient to reduce cognitive deficits. Neuroprot…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…